Markets BTIG starts NeuBase Therapeutics at buy; PT $15 BTIG initiated coverage of NeuBase Therapeutics (NASDAQ:NBSE) with a “buy” rating and $15 price target. The stock closed at $6.55 on Sept. 23. NeuBase has developed a modular antisense peptide nucleic acid (PNA)... September 24, 2019